Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.

Note: This column describes the author’s own experiences with Protonix (pantoprazole), Prograf (tacrolimus), Rapamune (sirolimus), and Forteo (teriparatide injection). Not everyone will have the same ...

It took a while for columnist Kylene Henderson's husband, Donnie, to be diagnosed with an autoimmune disease that led to ...

The activity levels of four genes linked to the Notch pathway could help in achieving an earlier diagnosis of idiopathic ...

I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” Danoff is also a professor of ...

The European Medicines Agency has granted orphan drug status to LTI-03, an inhaled therapy being developed for people with IPF.

Artificial intelligence (AI) touches many aspects of both our professional and personal lives. One of the earliest recognitions of AI dates back more than 75 years to when Alan Turing, an English ...

On New Year’s Day, my daughters and I created vision boards for 2026. If you haven’t made one before, a vision board is a collage of images, quotes, and art that captures your goals and intentions for ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

Over the holidays, for the first time in a long while, my home was full of voices, laughter, movement, and the comfort of family. I hosted the gathering, something I hadn’t been able to do in years.